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OBJECTIVE—The worldwide prevalence of obesity is increas-
ing at an alarming rate, along with the associated increased rates
of type 2 diabetes, heart disease, and some cancers. While efforts
to address environmental factors responsible for the recent
epidemic must continue, investigation into the anorectic func-
tions of potential molecules we present here, such as apolipopro-
tein (apo)E, offers exciting possibilities for future development
of successful anti-obesity therapies.
RESEARCH DESIGN AND METHODS—Changes in feeding
behavior after intracerebroventricular injection of apoE, the
regulation of hypothalamic apoE gene expression by energy
status, and the interaction of hypothalamic apoE with other
neuropeptides were studied.
RESULTS—Intracerebroventricular apoE signiﬁcantly de-
creased food intake without causing malaise, whereas intracere-
broventricular infusion of apoE antiserum stimulated feeding,
implying that endogenous apoE tonically inhibits food intake.
Consistent with this, apoE was present in the hypothalamus, a
brain site intimately involved in the integration of signals for
energy homeostasis. Fasted rats exhibited signiﬁcantly de-
creased apoE gene expression in the hypothalamus, and refeed-
ing of these rats for 4 h evoked a signiﬁcant increase of
hypothalamic apoE mRNA levels. Both genetically obese (ob/ob)
mice and rats with high-fat diet–induced obesity had signiﬁcantly
reduced hypothalamic apoE mRNA levels compared with their
lean control counterparts, suggesting that decreased apoE may
contribute to hyperphagia in these obese animals. Additionally,
apoE-stimulated hypothalamic proopiomelanocortin gene ex-
pression and SHU9119, a melanocortin 3/4 receptor antagonist,
attenuated the inhibitory function of apoE on feeding.
CONCLUSIONS—These data demonstrate that apoE sup-
presses food intake via a mechanism enhancing melanocortin
signaling in the hypothalamus. Diabetes 57:2092–2098, 2008
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levated body weight resulting in obesity is a
major health problem in the U.S. and is associ-
ated with signiﬁcant morbidity and mortality
from coronary heart disease, type 2 diabetes,
and other disorders. One well-established risk factor for
becoming obese is food consumption in excess of energy
expenditure. Evidence links a complex circuitry in the
mediobasal hypothalamus with the control of food intake
and energy expenditure. Obese animals have a blunted
response to satiation signals such as leptin and insulin,
raising the possibility that defective satiation signaling
within the central nervous system and/or peripheral tis-
sues may contribute to the etiology of obesity.
Apolipoprotein (apo)E, a 34,000-kDa glycoprotein in-
volved in lipid metabolism (1), is predominantly produced
in the liver and brain (2). Recent data suggest that apoE
plays additional roles in the brain, regulating both neuro-
nal and astrocyte functions, including preventing excito-
toxicity (3), promoting neuron survival and sprouting (4),
protecting neurons against oxidative stress (5), and regu-
lating innate and adaptive immune responses (6). We here
describe a novel and critical role of brain apoE in the
regulation of food intake.
Because targeted absence of apoE yields signiﬁcantly
elevated food intake and body weight in mice fed a
diabetogenic diet (7), we hypothesized that apoE partici-
pates in regulating energy homeostasis. In support of our
hypothesis, we found that 1) intracerebroventricular ad-
ministration of apoE signiﬁcantly reduces food intake and
body weight without causing malaise, whereas intracere-
broventricular infusion of apoE antiserum stimulates feed-
ing; 2) apoE is present in the arcuate nucleus (ARC) and
paraventricular nucleus (PVN) of the hypothalamus; 3)
genetically obese (ob/ob) mice and high-fat (HF) diet–
induced obese rats have signiﬁcantly reduced hypotha-
lamic apoE mRNA levels; 4) hypothalamic apoE gene
expression is regulated by nutritional status; and 5) apoE
exerts its anorectic action by interacting with the central
melanocortin system.
RESEARCH DESIGN AND METHODS
Animals and surgical procedures. Male adult Long-Evans rats (Harlan,
Indianapolis, IN) and male ob/ob and wild-type C57BL/6J mice (Jackson
Laboratory, Bar Harbor, ME) were individually housed in a temperature-
controlled vivarium on a 12/12-h light/dark cycle (lights on at 0200 h,
except where noted). Laboratory chow (Purina 5001, Hudson, NH) and
water were provided ad libitum except where noted. All procedures were
approved by the Institutional Animal Care and Use Committee of the
University of Cincinnati.
Rats anesthetized with ketamine (80 mg/kg)/xylazine (1.6 mg/kg) were
implanted with 22-gauge stainless steel cannulas (Plastics One, Roanoke, VA)
aimed at the third-cerebral ventricle. Coordinates were 2.2 mm posterior to
bregma and 7.4 mm ventral to dura as described previously (8,9). Placement
was conﬁrmed 5 days later by administration of 10 ng angiotensin II in saline
while the animals were water replete. Animals that did not drink at least 5 ml
water within 30 min were considered to have failed cannula placement and
were not used. Animals were allowed at least 7 days recovery before
commencement of experimentation.
To implant intravenous cannulas, the skin was incised between the right
front paw and the chin. The jugular vein was clamped 1 cm anterior to the
external/internal branching, and a sterile silicon catheter containing heparin-
ized saline was inserted with the tip positioned in the right atrium. The
catheter was secured with sutures on both sides of the silicon ring. The
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2092 DIABETES, VOL. 57, AUGUST 2008catheter was passed subcutaneously to the top of the skull and connected to
a piece of stainless steel tubing, which was secured by dental acrylic to the
skull screws. To prevent clotting, the catheter was maintained with a heparin
solution.
Materials. Rat apoE was puriﬁed from plasma obtained from abdominal
aorta blood of Sprague-Dawley rats. The plasma was centrifuged at a density
of 1.065 g/ml to isolate apoB-containing lipoproteins. After dialysis to
remove KBr, apolipoproteins in the HDL and greater were separated by
SDS-PAGE and puriﬁed by gel extraction as described previously (10). We
performed analytical PAGE on the isolated apoE and found only a single band
consistent with the molecular weight of apoE protein (11). Goat polycolonal
anti-apoE antiserum (Santa Cruz Biotechnology, Santa Cruz, CA) (12,13) and
SHU9119 (Phoenix Pharmaceuticals, Mountain View, CA) were used.
Food intake in ad libitum–fed and fasted rats. Food intake of each rat was
measured for at least 3 days to establish a baseline. On test days, ad
libitum–fed rats were weighed and food was removed 2 h before the beginning
of the dark cycle. Other rats were fasted for 24 h before lights off. Rats in both
conditions received intracerebroventricular apoE in saline at doses of 0, 1, 2,
4, or 8 g/rat just before dark. Infusions were delivered at a rate of 1 l/min
(total 4 l). Food intake was recorded after 0.5, 1, 2, and 4 h.
Conditioned taste aversion. Rats were adapted to 1-h daily access to
water (available in two bottles) for 10 days. On day 11, rats were given
0.15% saccharin in water in each bottle for the 1-h period instead of water
and then were injected with apoE (4 or 8 g/rat i.c.v.). Other rats received
LiCl as a positive control (0.15 mol/l; 127 mg/kg i.p.). On days 12–13,
animals had water in both bottles during the 1-h session, and on the test
day (day 14), rats were presented with one bottle containing saccharin and
one containing water. Saccharin preference ratio was calculated as the
amount of saccharin consumed divided by the total consumption of both
liquids over the hour.
Intracerebroventricular injection of apoE antibody. Rats with intracere-
broventricular cannulas were subdivided into three groups of equal body
weight. ApoE antibody (20 and 40 g protein in 4 l sterile saline) was
administered intracerebroventricularly at a rate of 1 l/min, starting at 1100 h,
in the middle of the light period when rats normally eat very little. As a
control, pre-absorbed apoE antiserum (40 g protein) was infused intracere-
broventricularly at the same rate. Preabsorbed apoE antiserum was generated
using cyanogens-bromide–activated agarose matrices (Sigma) according to
the manufacturer’s instruction. Feeding and drinking behavior were observed
for 60 min after the injections.
In a subsequent experiment, rats were divided into four groups. Groups 1
and 2 received intracerebroventricular saline (2 l), and groups 3 and 4
received intracerebroventricular apoE antiserum (20 g protein/rat) 30 min
before dark. Thirty minutes later, groups 1 and 3 received 4 l saline
intracerebroventricularly, and groups 2 and 4 received intracerebroventricular
apoE (4 g/rat). Food intake was measured after 2 h.
Western blot analysis. Hypothalamus samples were homogenized and
centrifuged at 15,000 rpm for 20 min at 4°C. The supernatant (containing 40 g
protein per sample) was separated by 12% polyacrylamide gel electrophoresis,
transferred to nitrocellulose sheets, and blotted with a polyclonal antibody
against apoE (1:1,000). Immunocomplexes were quantitated using an en-
hanced chemiluminescence detection system (Amersham Pharmacia Biotech,
Piscataway, NJ). Blots were stripped and re-incubated with a monoclonal
antibody against actin (1:10,000; Chemicon International). Membranes were
exposed to X-ray ﬁlm (Kodak Scientiﬁc Imaging Film; Kodak, Rochester, NY),
and ﬁlm density, measured as transmittance, was expressed as volume-
adjusted optical density. The amount of apoE protein was normalized to the
respective individual density values reﬂecting actin protein level and is
expressed as a ratio.
Immunohistochemistry. Rats were anesthetized with sodium pentobarbital
(50 mg/kg i.p.) and then perfused via the ascending aorta with 100 ml of a 0.9%
NaCl solution followed by 500 ml of ice-cold 4% paraformaldehyde in 0.1 mol/l
phosphate buffer (pH 7.4). Brains were removed and placed in perfusion
b u f f e rf o r4ha t4 ° Ca n dthen in buffered sucrose (30%) for at least 24 h, and
30-m serial coronal sections were cut using a microtome. After washing,
sections were blocked with 5% normal donkey serum in PBS containing 0.3%
Triton X-100 for 2 h. Then, sections were incubated with goat anti-apoE
antiserum (1:400) overnight at 4°C. The secondary antibody was donkey
anti-goat immunoglobulin conjugated to ﬂuorescein Alexa 594 (1:400; Molec-
ular Probes). Imaging was performed on a Zeiss 510 microscope system.
Omission of the primary antibody and substituting the primary antibody with
apoE preabsorbed serum conﬁrmed antibody speciﬁcity.
Quantitative PCR for apoE mRNA measurement. Total RNA (100 ng),
extracted from hypothalamus with Tri Reagent (Molecular Research Center,
Cincinnati, OH), was reverse-transcribed to ﬁrst-strand complementary cDNA
(GE Healthcare Bio-Sciences, Piscataway, NJ). Quantitative real-time PCR
(qPCR) was performed in a 25-l ﬁnal reaction volume with an iCycler iQ
Detection System using iQ SYBR Green Supermix (Bio-Rad Laboratories,
Hercules, CA). qPCR conditions were as follows: 95°C for 3 min for one cycle,
followed by 38 cycles of 95°C for 30 s and 58°C for 30 s. Melt curve analysis
revealed one peak per sample. Threshold cycle (Ct) readings for unknown
samples were calculated, and results were analyzed using the delta-delta CT
method (Perkin-Elmer Applied Biosystems) (14). Other neuropeptide mRNA
levels, including proopiomelanocortin (POMC), neuropeptide Y (NPY), and
agouti-related protein (AgRP), were examined likewise. Cyclophilin was used
as the internal control. Primer sequences, listed in Table 1, for rat and mouse
apoE, rat POMC, NPY, AgRP, and cyclophilin were determined using primer
design software (Integrated DNA Technologies, Coralville, IA).
Rats with HF diet–induced obesity. Two pelleted semi-puriﬁed nutrition-
ally complete experimental diets prepared by Dyets (Bethlehem, PA) were
used. As described previously (15), the HF diet contained 20 g fat (19 g butter
oil and 1 g soybean oil)/100 g diet, and the low-fat (LF) diet contained4gf a t
(3 g butter oil and 1 g soybean oil)/100 g diet by weight. Rats were divided into
three groups, with HF rats allowed ad libitum access to HF diet, LF rats
allowed ad libitum access to LF diet, and a pair-fed HF group fed HF diet each
day in an amount limited to the average daily caloric consumption of the rats
fed the LF diet. Rats were maintained on their diet for 10 weeks, throughout
which the mean energy intake of the LF and the pair-fed HF rats was 83% of
that of the HF group (15). After 10 weeks, rats were fasted overnight and
decapitated, and hypothalami were dissected and stored at 80°C until
measurement of apoE mRNA.
Effects of apoE on the gene expression of neuropeptides in the
hypothalamus. We investigated the effects of apoE on gene expression of
several neuropeptides in four groups of rats. Groups 1 and 2 were ad
libitum–fed, and groups 3 and 4 were fasted for 46 h. Groups 2 and 4 received
intracerebroventricular apoE (8 g), and groups 1 and 3 received intracere-
broventricular saline. Rats were killed 2 h after injections, and hypothalamic
gene expression was characterized using qPCR measurement of POMC, NPY,
and AgRP.
Effect of SHU9119 on apoE-elicited suppression of food intake and
body weight. Rats were fasted 4 h before lights-off (1400 h) and received two
injections on the test day: saline (vehicle for SHU9119)  saline (vehicle for
apoE), saline  apoE (2 g), SHU9119 (0.1 nmol)  saline, and SHU9119 (0.1
nmol)  apoE (2 g). The dose of SHU9119 has been reported to have no
effect on food intake or body weight of rats (16). The ﬁrst injection occurred
at 1330 h and was followed 30 min later by the second injection. Food was
then returned, and intake was measured after 4 h. Every rat was subjected to
each treatment, with at least 5 days between tests.
Statistical analysis. Data were analyzed using parametric statistics (Sigma
Stat version 3.1). Two-way repeated-measures ANOVA followed by Tukey’s
test was used for analysis of food intake. For other comparisons, i.e., apoE or
other gene mRNA levels, either a one-way ANOVA (for more than a two-group
comparison) followed by Tukey’s test or an unpaired Student’s t test (for
two-group comparison) was used. P values 0.05 were considered statisti-
cally signiﬁcant.
TABLE 1
Primer sequences and product size for qPCR
Accession number Forward primer Reverse primer Size (bp)
Rat apoE BC086581 5-ttggtcccattgctgacag-3 5-accgtcagttcctgtgtgac-3 189
Mouse apoE BC044785 5-aacagacccagcaaatacgcc-3 5-ctcattgattctcctgggcc-3 154
POMC NM_139326 5-cgcccgtgtttcca-3 5-tgacccatgacgtacttcc-3 69
NPY NM_012614 5-ccttgcgacactacatcaa-3 5-ggggcattttctgtgcttt-3 108
AgRP AF206017 5-ttcccagagttctcaggtcta-3 5-atctagcacctctgccaaa-3 98
Cyclophilin M19533 5-attcatgtgccagggtggtgac-3 5-tcagtcttggcagtgcagat-3 182
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Intracerebroventricular apoE suppressed food in-
take. To examine the effect of apoE on food intake, we
administered doses from 1 to 8 g of apoE into the
third-cerebral ventricle of rats. As depicted in Fig. 1,
intracerebroventricular apoE at doses 2 g produced a
signiﬁcant and dose-dependent inhibition of food intake in
both ad libitum (Fig. 1A) and 24 h–fasted (Fig. 1B)
conditions. To determine whether the central nervous
system is the critical site of action for intracerebroventric-
ular apoE, intake of rats administered apoE intravenously
at doses that were effective centrally (4 and 8 g) did not
differ in food intake from those receiving vehicle at any
time point, implying that intracerebroventricular apoE
acts within the central nervous system to suppress food
intake rather than leaking into the blood and acting at
peripheral apoE receptors.
Reduction of food intake was not associated with
illness. To determine whether apoE-induced reduction in
food intake is secondary to illness, a conditioned taste
aversion paradigm was conducted (8). Rats receiving
saccharin paired with intracerebroventricular apoE (4 or 8
g) had comparable preference for saccharin, as did the
saline controls (Fig. 2). Animals receiving LiCl paired with
saccharin consumed signiﬁcantly less saccharin than the
controls (P  0.01), indicating that malaise is not a factor
in the suppressive activity of apoE on food intake.
Intracerebroventricular apoE antiserum stimulated
food intake and attenuated the anorectic effect of
apoE. To determine whether endogenous apoE signaling
inﬂuences food intake, we administered apoE antiserum
intracerebroventricularly to ad libitum–fed rats in the
middle of the light. ApoE antiserum elicited feeding and
signiﬁcantly increased mean food intake (Fig. 3A); pran-
dial drinking also increased (data not shown). No adverse
physiological reactions such as sedation or ataxia were
observed. The intracerebroventricular infusion of preab-
sorbed apoE serum failed to elicit a feeding response. A
subsequent experiment determined if apoE antiserum
could speciﬁcally block apoE anorectic action. As de-
picted in Fig. 3B, intracerebroventricular apoE alone sig-
niﬁcantly reduced food intake, and this effect was
attenuated by the antibody at 2 h.
ApoE is present in the hypothalamus. Using apoE
antiserum, Western immunoblotting of hypothalamic pro-
teins revealed an immunoreactive band of weight 34,000
kDa (Fig. 4A), corresponding to the molecular weight of
rat apoE (11). Signal abolition by preabsorbing the anti-
body with puriﬁed rat apoE conﬁrmed antibody speciﬁcity
(Fig. 4B). To localize the distribution of apoE in the
hypothalamus we used immunoﬂuorescence labeling and
observed a prominent presence of apoE protein in the
ARC (Fig. 4C) and PVN (Fig. 4D). No immunoreactivity
was observed in brain sections of apoE KO mice treated
likewise, further conﬁrming speciﬁcity of immunostaining.
The distribution of apoE in the brain is consistent with a
role in the regulation of energy homeostasis (17).
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of genetically obese (ob/ob) mice and rats with HF-
diet–induced obesity. ob/ob mice are a well-known ani-
mal model for obesity (18). Using qPCR, we found that
apoE mRNA levels are signiﬁcantly reduced in the hypo-
thalami of ob/ob mice compared with those in lean control
animals (P  0.05, Fig. 5A). To determine whether diet-
induced obesity alters apoE gene expression in the hypo-
thalamus, rats were fed an HF or LF diet for 10 weeks,
after which the body weight of HF rats was signiﬁcantly
heavier than that of the other groups. As expected, pair-fed
HF rats weighed less than HF rats (P  0.05) and were not
different from the LF rats (data not shown), consistent
with what we have reported previously (15). Compared
with LF rats, HF rats had signiﬁcantly reduced hypotha-
lamic apoE gene expression. Hypothalamic apoE levels of
the LF and pair-fed HF groups were not statistically
different (Fig. 5B).
Hypothalamic apoE mRNA was regulated by fasting
and chow refeeding. To examine whether brain apoE is
inﬂuenced by energy status, we measured hypothalamic
apoE mRNA levels by qPCR in rats that were ad
libitum–fed, 36 h–fasted, and 32 h–fasted followed by
4-h refeeding. Animals were killed in the dark phase
(2200 h, lights off at 1800 h). Fasted rats lost 12% (from
273.4  12.4 to 241.2  11.8 g) of their body weight and
had signiﬁcantly reduced hypothalamic apoE mRNA
levels compared with ad libitum–fed controls (0.64 
0.05 vs. 1.0  0.13; P  0.05) (Fig. 5C). ApoE mRNA
expression was completely reversed to levels of ad
libitum–fed rats after4ho frefeeding (1.18  0.19) (Fig.
5C).
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induced by fasting. The 48-h fasting signiﬁcantly reduced
POMC mRNA levels (P  0.05), and intracerebroventricu-
lar apoE prevented this reduction, demonstrating the
stimulatory effect of apoE on hypothalamic POMC gene
expression (Fig. 6). Consistent with a previous report (19),
48-h fasting signiﬁcantly increased both NPY and AgRP
mRNA levels. After apoE administration, there was a trend
toward decreased NPY and AgRP gene expression, but it
was not statistically signiﬁcant (data not shown).
ApoE-induced reduction of food intake was attenu-
ated by SHU9119. The hypothalamic melanocortin sys-
tem is important in the regulation of food intake and body
weight (16,20). We hypothesized that apoE interacts with
the central melanocortin system to control food intake. If
so, then blockade of downstream melanocortin recep-
tor(s) should either block or attenuate the inﬂuence of
apoE on food intake. To evaluate this possibility, a sub-
threshold dose (0.1 nmol) of SHU9119, an antagonist
speciﬁc for the melanocortin-3/4 receptors, was adminis-
tered concomitantly with apoE in rats. As depicted in Fig.
7, intracerebroventricular SHU9119 alone did not produce
a reliable effect on food intake, whereas 2 g apoE
signiﬁcantly reduced food intake 4 h after injection. How-
ever, when the two injections were combined, the
SHU9119 completely attenuated the anorectic effect of
apoE, implying that an interaction occurs between apoE
and the melanocortin system with regard to feeding regu-
lation by the brain.
DISCUSSION
We have demonstrated for the ﬁrst time that centrally
administered apoE suppresses food intake dose-depen-
dently and without malaise. Taken with the fact that
comparable doses of apoE administered systemically have
no effect on food intake, this anorectic action likely occurs
within the brain. Moreover, when apoE antiserum was
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FIG. 6. Hypothalamic POMC mRNA levels measured by qPCR. The 48 h
of fasting caused a signiﬁcant reduction of POMC mRNA levels, which
were reversed by intracerebroventricular administration of apoE (8
g). Data are means  SE, n  7. *P < 0.05 vs. the ad libitum–fed saline
group. #P < 0.05 vs. 48-h–fasted saline controls.
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FIG. 7. Cumulative food intake in rats at 4 h after apoE (2 g),
SHU9119 (0.1 nmol), or saline treatments. Data are means  SE, n 
8–9. *P < 0.05 vs. saline  saline group. #P < 0.05 vs. saline  apoE
group.
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rats during the light cycle (when rats normally eat very
little), increased food intake was observed, and intracere-
broventricularly infusion of preabsorbed apoE antiserum
failed to elicit feeding. This implies that apoE antiserum
neutralizes endogenous apoE present in a brain area with
access to the third ventricle and suggests that endogenous
apoE might provide an important tonic inhibition of food
intake. The observation that the anorectic effect of apoE
was signiﬁcantly attenuated by apoE antiserum further
supports that the effect is speciﬁc to apoE.
We found that apoE is highly expressed in the ARC and
PVN of the hypothalamus, key areas in the regulation of
energy homeostasis (17). Obesity is a complex metabolic
problem, and evidence indicates that obese animals have
blunted satiation, raising the possibility that defective
satiation signaling in the brain may contribute to the
etiology of obesity (21). Our data implicate apoE as a
physiological regulator of food intake, such that impair-
ment in apoE production could lead to chronic increases
in meal size resulting in obesity. Consistent with this, we
observed signiﬁcantly lower levels of hypothalamic apoE
mRNA in genetically obese mice (ob/ob) compared with
lean controls, which also suggests that reduced apoE
levels contribute to hyperphagia of these obese animals.
Epidemiological studies yield a signiﬁcant positive cor-
relation between average dietary fat intake and the inci-
dence of obesity (22,23). Using an HF-induced obese rat
model (24), we conﬁrmed that hypothalamic apoE mRNA
levels are signiﬁcantly lower than in LF-fed rats, which
directed us to assess if altered apoE gene expression
results from HF diet exposure or the resultant obesity.
Rats with restricted caloric intake of HF diet neither
became obese nor had decreased hypothalamic apoE gene
expression, suggesting that reduced apoE gene expression
after HF diet consumption is secondary to consequent
obesity and not due to mere exposure to HF diet itself.
Leptin acts in the hypothalamus to decrease food intake
and increase energy expenditure (25) through its long
form of the receptor (Ob-Rb) (26,27), which is highly
expressed in the rat hypothalamus, especially in the ARC
(28). Our data from ob/ob mice (leptin-deﬁcient) and
HF-induced obese rats (leptin-resistant) suggest that a
deﬁciency in leptin signaling may be related in part to the
altered apoE gene expression in the hypothalamus. Fur-
ther support comes from the observation that fasting-
induced reduced leptin levels are associated with reduced
hypothalamic apoE mRNA levels. Leptin’s facilitation of
the gene expression of apoE and anorectic effects will be
explored in future experiments.
Caloric deprivation invokes a complex array of neural
and metabolic responses to reduce energy expenditure,
one of which is an increased drive to eat related to the
alteration of neuropeptide gene expression in the hypo-
thalamus (29). Food deprivation increases hypothalamic
AgRP and NPY gene expression, but decreases POMC
mRNA levels in the hypothalamus (30). Consistent with
the change in POMC, we demonstrated that hypothalamic
apoE mRNA levels also decreased when the animals were
fasted for 36 h compared with those in ad libitum–fed rats.
This diminished gene expression was completely restored
by refeeding, indicating that hypothalamic apoE mRNA is
indeed regulated by energy status. These observations are
potentially critical and strongly suggest a physiological
role of apoE in the regulation of food intake.
Compelling evidence suggests that food intake and body
weight are controlled by neuropeptides acting within the
central nervous system, and this circuitry can be concep-
tually divided into anabolic and catabolic systems. NPY,
AgRP, and POMC are key peptides in these systems,
respectively (29), and the balance between these systems
ultimately determines the animal’s ingestive behavior and
energy expenditure (17,29). We hypothesized that apoE
exerts its anorectic action by interacting with these neu-
ropeptides and therefore assessed the effects of intracere-
broventricular apoE administration on hypothalamic
POMC, NPY, and AgRP gene expression in 48 h–fasted
rats. ApoE treatment prevented the reduction of POMC
mRNA observed in fasted rats (Fig. 6), implying that apoE
exerts its anorectic action by enhancing activity of the
melanocortin system.
Given this ﬁnding, it could be further hypothesized that
blockade of downstream melanocortin receptor(s) will
block or attenuate the anorectic action of apoE. In a
subsequent experiment, a subthreshold dose of SHU9119
(0.1 nmol), an antagonist speciﬁc for the melanocortin-3
and melanocortin-4 (MC3/4) receptors, was administered
concomitantly with apoE. This resulted in complete abo-
lition of apoE-induced satiety (Fig. 7), indicating that an
interaction indeed occurs between apoE and the melano-
cortin system with regard to the control of feeding by the
brain.
Molecular mechanisms mediating the anorectic action
of apoE currently remain unclear. Because apoE exerts its
physiological function through its receptors, most of
which are in neurons (31), the secreted apoE likely binds
to its receptors, perhaps located on POMC neurons. Acti-
vation of apoE receptors might stimulate POMC gene
expression, from which the 	-melanocyte–stimulating hor-
mone is cleaved and released. The liberated 	-melano-
cyte–stimulating hormone could bind melanocortin-3/4
receptors to reduce food intake and body weight. Detailed
molecular mechanisms of how apoE increases POMC gene
expression requires further study.
As the prevalence of obesity is rapidly increasing world-
wide and efforts to address the environmental factors
responsible for this epidemic are slowly gaining ground, a
deeper molecular and physiologic understanding of obe-
sity must be pursued to combat obesity from multiple
angles with various therapeutic approaches. We have
revealed apoE as an important regulator of food intake
and body weight. Characterization of the central effect of
apoE on feeding should stimulate further research into the
physiological functions of this protein, and mechanistic
understanding mediating the anorectic function of apoE
may lead to the development of effective new treatments
for human obesity and related disorders.
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